Microwave ablation (MWA) may be a safe and effective treatment for patients with secondary hyperparathyroidism (SHPT), according to investigators.
Ming-An Yu, MD, PhD, of China-Japan Friendship Hospital in Beijing, and colleagues conducted a meta-analysis of 2 retrospective cohort studies and 6 self-control studies that included 233 patients with SHPT. Parathyroid hormone (PTH) levels significantly declined from baseline over 1 day, 1 week, 1 month, and 6 months of MWA, with weighted mean differences of 890, 860, 801, and 861 pg/mL, respectively. Serum calcium and phosphorus levels also significantly declined over 1 day and 1 week of MWA, but phosphorus fluctuated thereafter, according to results published in the International Journal of Hyperthermia.
With respect to adverse events, hypocalcemia developed in 15.8% of patients treated with MWA, which is lower than the rate after parathyroidectomy. Another 1.2% of MWA patients experienced nerve injury. Temporary hoarseness occurred in 4.2%, which is higher than after parathyroidectomy. MWA is an option for patients who are not suitable candidates for surgery.
“Compared with other thermal ablation techniques [radiofrequency, laser and high-intensity focused ultrasound], MWA may translate into larger and more consistent ablation zones in less time,” Dr Yu’s team wrote..
Cao X-J, Zhao Z-L, Wei Y, et al. Efficacy and safety of microwave ablation treatment for secondary hyperparathyroidism: systematic review and meta-analysis. Intl J Hyperthermia. 2020;37:316-323. doi: 10.1080/02656736.2020.1744741